|Vinorelbine plus cisplatin vs. observation in resected non–small-cell lung cancer|
T Winton, R Livingston, D Johnson, J Rigas, M Johnston, C Butts, ...
New England Journal of Medicine 352 (25), 2589-2597, 2005
|Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review|
JJ Caro, M Salas, A Ward, G Goss
Cancer 91 (12), 2214-2221, 2001
|Probability of cancer in pulmonary nodules detected on first screening CT|
A McWilliams, MC Tammemagi, JR Mayo, H Roberts, G Liu, K Soghrati, ...
New England Journal of Medicine 369 (10), 910-919, 2013
|Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non–small-cell lung cancer|
C Butts, N Murray, A Maksymiuk, G Goss, E Marshall, D Soulières, ...
Journal of Clinical Oncology 23 (27), 6674-6681, 2005
|Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study|
G Goss, CM Tsai, FA Shepherd, L Bazhenova, JS Lee, GC Chang, ...
The lancet oncology 17 (12), 1643-1652, 2016
|Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non–small-cell lung cancer: updated survival analysis …|
CA Butts, K Ding, L Seymour, P Twumasi-Ankrah, B Graham, D Gandara, ...
Journal of clinical oncology 28 (1), 29, 2010
|Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial|
JC Soria, E Felip, M Cobo, S Lu, K Syrigos, KH Lee, E Göker, ...
The lancet oncology 16 (8), 897-907, 2015
|A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas|
I Duran, J Kortmansky, D Singh, H Hirte, W Kocha, G Goss, L Le, A Oza, ...
British journal of cancer 95 (9), 1148-1154, 2006
|Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials|
TR Asmis, K Ding, L Seymour, FA Shepherd, NB Leighl, TL Winton, ...
Journal of Clinical Oncology 26 (1), 54-59, 2008
|Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non–small-cell lung cancer|
RB Natale, S Thongprasert, FA Greco, M Thomas, CM Tsai, ...
Journal of Clinical Oncology 29 (8), 1059-1066, 2011
|Gefitinib versus placebo in completely resected non–small-cell lung cancer: results of the NCIC CTG BR19 study|
GD Goss, C O'Callaghan, I Lorimer, MS Tsao, GA Masters, J Jett, ...
Journal of clinical oncology 31 (27), 3320, 2013
|Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non–small-cell lung cancer: NCIC Clinical Trials Group BR24 …|
GD Goss, A Arnold, FA Shepherd, M Dediu, TE Ciuleanu, D Fenton, ...
Journal of Clinical Oncology 28 (1), 49-55, 2010
|The effect of low‐molecular‐weight heparin on cancer survival. A systematic review and meta‐analysis of randomized trials|
A Lazo‐Langner, GD Goss, JN Spaans, MA Rodger
Journal of Thrombosis and Haemostasis 5 (4), 729-737, 2007
|Apixaban to prevent venous thromboembolism in patients with cancer|
M Carrier, K Abou-Nassar, R Mallick, V Tagalakis, S Shivakumar, ...
New England Journal of Medicine 380 (8), 711-719, 2019
|Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy …|
AM Arnold, L Seymour, M Smylie, K Ding, Y Ung, B Findlay, CW Lee, ...
Journal of Clinical Oncology 25 (27), 4278-4284, 2007
|Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label …|
C Butts, A Maksymiuk, G Goss, D Soulieres, E Marshall, Y Cormier, ...
Journal of cancer research and clinical oncology 137 (9), 1337-1342, 2011
|Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC): A study of the National Cancer Institute of Canada Clinical Trials Group|
Y Cormier, E Eisenhauer, A Muldal, R Gregg, J Ayoub, G Goss, D Stewart, ...
Annals of oncology 5 (3), 283-285, 1994
|Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non–small-cell lung cancer and poor performance status|
G Goss, D Ferry, R Wierzbicki, SA Laurie, J Thompson, B Biesma, ...
Journal of clinical oncology 27 (13), 2253, 2009
|Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non–small-cell lung cancer|
SJ Crabb, D Patsios, E Sauerbrei, PM Ellis, A Arnold, G Goss, NB Leighl, ...
Journal of Clinical Oncology 27 (3), 404-410, 2009
|CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials|
G Goss, CM Tsai, FA Shepherd, MJ Ahn, L Bazhenova, L Crinò, ...
Annals of Oncology 29 (3), 687-693, 2018